RESP-FIT: A Respiratory Muscle Strength Training Intervention for COPD
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Mary Chris S. Pittman, BA
- Phone Number: 8437923512
- Email: pittmama@musc.edu
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥40 years
- Clinical diagnosis of COPD
- Ability to provide informed consent
- Willingness to use mobile health devices and apps
- Access to Wi-Fi and mailing address in the U.S.
Exclusion Criteria:
- Cognitive impairment preventing participation
- Active substance abuse
- Other significant respiratory disease
- Concurrent enrollment in conflicting COPD or behavioral intervention trials
- Non-English speaking
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: RESPFIT Intervention Arm
The RESP-FIT intervention group will receive the full intervention, including respiratory muscle strength training (RMST), ecological momentary assessment (EMA) symptom tracking through the mobile application, and physical activity monitoring using an activity monitor.
Participants will receive instructions from study personnel on RMST device use and will follow a simple 5x5x5 training protocol (5 breaths, 5 times a day, 5 times a week) over the intervention period.
Participants will be asked to record training sessions and symptoms using the mobile application.
The intervention period will last 6 months, with the primary endpoint occurring at 3 months following baseline.
Outcome assessments will occur at baseline and at 1, 2, 3, and 6 months.
|
The RESP-FIT intervention group will receive the full intervention, including respiratory muscle strength training (RMST), EMA symptom management through the RESP-FIT app, ecological momentary assessment (EMA) symptom tracking through the mobile application, and physical activity monitoring using the Garmin activity monitor.
Participants will receive instructions from study personnel on RMST device use and will follow a simple 5x5x5 training protocol (5 breaths, 5 times a day, 5 times a week) over the intervention period of 6 months.
Participants will also be asked to record training sessions and symptoms using the mobile application.
Participants will receive on-going support and monitoring from study personnel for the first 3 months and can use app and devices at will for the next 3 months until the 6 month assessment period when the study procedures end.
|
|
No Intervention: No Intervention Enhanced Usual Care Group
Participants randomized to the control group will receive enhanced usual care (eUC).
This consists of their standard COPD management provided by their healthcare providers along with the mobile app for remote spirometry and symptom tracking and physical activity monitoring using the Garmin wearable activity tracker.
Control group participants will also receive publicly available COPD educational materials (via COPD Foundation resources).
Providing an activity monitor to both groups allows the research team to account for potential effects of activity monitoring on physical activity behavior.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Maximal Inspiratory Pressure (PImax)
Time Frame: Baseline to 3 Months
|
Maximal inspiratory pressure measured using the POWERbreathe Smart Adaptor digital pressure transducer connected to a mouthpiece.
|
Baseline to 3 Months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Modified Borg Dyspnea Scale Score
Time Frame: Baseline to 3 Months
|
Dyspnea severity assessed using the Modified Borg Scale delivered through ecological momentary assessment (EMA) within the study mobile application.
Scores range from 0-10, with 0 indicating no breathlessness and 10 indicating maximal breathlessness.
Higher scores indicate greater dyspnea severity.
|
Baseline to 3 Months
|
|
Change in Breathlessness Beliefs Questionnaire (BBQ) Score
Time Frame: Baseline to 3 Months
|
Dyspnea-related kinesiophobia assessed using the Breathlessness Beliefs Questionnaire (BBQ), a validated 11-item instrument that measures dysfunctional beliefs about breathlessness related to physical activity.
Items are rated on a 5-point scale, yielding a total score ranging from 11-55, with higher scores indicating stronger beliefs about breathlessness and greater dyspnea-related fear and activity avoidance.
|
Baseline to 3 Months
|
|
Change in Modified Medical Research Council (mMRC) Dyspnea Scale Score
Time Frame: Baseline to 3 Months
|
Breathlessness measured using the Modified Medical Research Council (mMRC) Dyspnea Scale, a 5-grade scale that assesses the degree to which breathlessness limits daily physical activities.
Scores range from 0-4, with higher scores indicating breathlessness that prevents leaving the house or occurring during dressing/undressing.
Higher scores indicate worse dyspnea-related functional limitation.
|
Baseline to 3 Months
|
|
Change in PROMIS Dyspnea-Related Activity Avoidance Score
Time Frame: Baseline to 3 Months
|
Activity avoidance due to breathing discomfort assessed using the PROMIS Dyspnea-Related Activity Avoidance instrument.
This is a 5 point Likert scale with 3 items measuring avoidance of activities due to shortness of breath or phsyical limitations over the past 7 days, scored from 0 (not at all) to 4 (very much), yielding total raw score range of 0-12.
Higher scores indicate greater dyspnea-related task avoidance.
|
Baseline to 3 Months
|
|
Change in St. George's Respiratory Questionnaire (SGRQ) Total Score
Time Frame: Baseline to 3 Months
|
Respiratory-related quality of life assessed using the St. George's Respiratory Questionnaire (SGRQ) for COPD.
This is contains 40 items assessing three domains (symptoms, activity, and impact) and a total score ranging from 0-100, with 0 indicating no impairment and 100 indicating maximum impairment.
Higher scores indicate greater impairment in respiratory related quality of life.
|
Baseline to 3 Months
|
|
Change in Average Daily Step Count
Time Frame: Baseline to 3 Months
|
Physical activity measured using a Garmin wearable activity monitor, with daily steps captured numerically in number of steps.
|
Baseline to 3 Months
|
|
Change in CAPTURE Score
Time Frame: Baseline to 3 Months
|
COPD symptoms and exacerbation risk assessed using the COPD Assessment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE) questionnaire.
This is a 5 item instrument assessing respiratory symptoms, risk exposures, recent acute respiratory illnesses with a total score range of 0-6, with higher scores indicating greater likelihood of clinically significant COPD and exacerbation risk.
|
Baseline to 3 Months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Qualitative Measures
Time Frame: 3 months
|
Semi-structured interviews assessing intervention accessibility, usability, symptom monitoring, dyspnea-related activity avoidance, disease self-management, and overall participant experiences with RESP-FIT
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Sarah Miller, PhD, RN, Medical University of South Carolina
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Pro00149990
- 1R01NR021347-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.